Table of Contents

Specific Acetylation of p53 by HDAC Inhibition Prevents DNA Damage-Induced Apoptosis in Neurons

  1. Brett Langley1,2
  1. 1The Burke Medical Research Institute, White Plains, New York 10605,
  2. 2Department of Neurology and Neuroscience, Weill Medical College of Cornell University, New York, New York 10065, and
  3. 3Department of Neurology, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, California 90095
  1. Author contributions: C.B., R.R.R., and B.L. designed research; C.B., G.D., M.A.R., K.M., and G.C. performed research; C.B., G.D., M.A.R., G.C., and B.L. analyzed data; C.B. and B.L. wrote the paper.

Abstract

Histone deacetylase (HDAC) inhibitors have been used to promote neuronal survival and ameliorate neurological dysfunction in a host of neurodegenerative disease models. The precise molecular mechanisms whereby HDAC inhibitors prevent neuronal death are currently the focus of intensive research. Here we demonstrate that HDAC inhibition prevents DNA damage-induced neurodegeneration by modifying the acetylation pattern of the tumor suppressor p53, which decreases its DNA-binding and transcriptional activation of target genes. Specifically, we identify that acetylation at K382 and K381 prevents p53 from associating with the pro-apoptotic PUMA gene promoter, activating transcription, and inducing apoptosis in mouse primary cortical neurons. Paradoxically, acetylation of p53 at the same lysines in various cancer cell lines leads to the induction of PUMA expression and death. Together, our data provide a molecular understanding of the specific outcomes of HDAC inhibition and suggest that strategies aimed at enhancing p53 acetylation at K381 and K382 might be therapeutically viable for capturing the beneficial effects in the CNS, without compromising tumor suppression.

  • Received November 8, 2012.
  • Revision received February 22, 2013.
  • Accepted March 18, 2013.